Conclusions
As reflected in the relevant milestones, there has undoubtedly been considerable knowledge gained in recent years on diagnosis and management of bacterial meningitis. Future research aims at specific anti-inflammatory measures, optimal treatment of meningitis caused by penicillin-resistant pneumococci, routine in vitro screening of new agents for potential neurotoxicity, and immunogenic, safe and protective conjugate vaccines for young infants. Hence, challenges remain.
Similar content being viewed by others
References
Friedland IR, McCracken GH (1994) Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 331:377–382
Kornelisse RF, Groot R de, Neijens HJ (1995) Bacterial meningitis: mechanisms of disease and therapy. Eur J Pediatr 154:85–96
Schaad UB, McCracken GH, Loock CA, Thomas ML (1981) Pharmacokinetics and bacteriological efficacy of moxalactam, cefotaxime, cefoperazone and ceftriaxone in experimental bacterial meningitis. J Infect Dis 143:156–163
Schaad UB, Guenin K, Steffen C, Herschkowitz N (1988) Effects of antimicrobial agents used for therapy of CNS infections on dissociated brain cell cultures. Pediatr Res 24:367–372
Schaad UB, Lips U, Gnehm HE, Blumberg A, Heinzer I, Wedgwood J, for the Swiss Meningitis Study Group (1993) Dexamethasone therapy for bacterial meningitis in children. Lancet 342:457–461
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schaad, U.B. Current concepts of bacterial meningitis. Eur J Pediatr 154 (Suppl 4), S20–S22 (1995). https://doi.org/10.1007/BF02191499
Issue Date:
DOI: https://doi.org/10.1007/BF02191499